Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 761939, 5 pages
http://dx.doi.org/10.1155/2015/761939
Research Article

Association of Plasma Myeloperoxidase Level with Risk of Coronary Artery Disease in Patients with Type 2 Diabetes

1Department of Endocrinology, Shandong Provincial Hospital, Shandong University, No. 324, Jing 5 Road, Jinan, Shandong 250021, China
2Shandong Clinical Medical Center of Endocrinology and Metabolism, No. 324, Jing 5 Road, Jinan, Shandong 250021, China
3Institute of Endocrinology and Metabolism, Shandong Academy of Clinical Medicine, No. 324, Jing 5 Road, Jinan, Shandong 250021, China
4Department of Cardiology, Shandong Provincial Hospital, Shandong University, No. 324, Jing 5 Road, Jinan, Shandong 250021, China

Received 16 February 2015; Revised 9 June 2015; Accepted 11 June 2015

Academic Editor: Irene Rebelo

Copyright © 2015 Ping Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Diabetes Association, “Screening for type 2 diabetes,” Diabetes Care, vol. 21, supplement 1, pp. S20–S22, 1998. View at Publisher · View at Google Scholar
  2. R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Karakas and W. Koenig, “Myeloperoxidase production by macrophage and risk of atherosclerosis,” Current Atherosclerosis Reports, vol. 14, no. 3, pp. 277–283, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. T. J. Mocatta, A. P. Pilbrow, V. A. Cameron et al., “Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction,” Journal of the American College of Cardiology, vol. 49, no. 20, pp. 1993–2000, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. W. H. W. Tang, Y. Wu, S. J. Nicholls, and S. L. Hazen, “Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease,” Clinical Chemistry, vol. 57, no. 1, pp. 33–39, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. C. L. Heslop, J. J. Frohlich, and J. S. Hill, “Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography,” Journal of the American College of Cardiology, vol. 55, no. 11, pp. 1102–1109, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. M. C. Meuwese, E. S. G. Stroes, S. L. Hazen et al., “Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study,” Journal of the American College of Cardiology, vol. 50, no. 2, pp. 159–165, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. I. A. A. Syed and W. A. Khan, “Glycated haemoglobin—a marker and predictor of cardiovascular disease,” Journal of the Pakistan Medical Association, vol. 61, no. 7, pp. 690–695, 2011. View at Google Scholar · View at Scopus
  9. Y. Zhang, G. Hu, Z. Yuan, and L. Chen, “Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis,” PLoS ONE, vol. 7, no. 8, Article ID e42551, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. J. J. Wiersma, M. C. Meuwese, J. N. I. Van Miert et al., “Diabetes mellitus type 2 is associated with higher levels of myeloperoxidase,” Medical Science Monitor, vol. 14, no. 8, pp. CR406–CR410, 2008. View at Google Scholar · View at Scopus
  11. K. Heilman, M. Zilmer, K. Zilmer et al., “Arterial stiffness, carotid artery intima-media thickness and plasma myeloperoxidase level in children with type 1 diabetes,” Diabetes Research and Clinical Practice, vol. 84, no. 2, pp. 168–173, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Rovira-Llopis, M. Rocha, R. Falcon et al., “Is myeloperoxidase a key component in the ROS-induced vascular damage related to Nephropathy in type 2 diabetes?” Antioxidants and Redox Signaling, vol. 19, no. 13, pp. 1452–1458, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Kataoka, M. Shao, K. Wolski et al., “Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: insights from intravascular ultrasound,” Atherosclerosis, vol. 232, no. 2, pp. 377–383, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Moldoveanu, C. Tanaseanu, S. Tanaseanu et al., “Plasma markers of endothelial dysfunction in type 2 diabetics,” European Journal of Internal Medicine, vol. 17, no. 1, pp. 38–42, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. WHO, World Health Organization Definition: Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1. Diagnosis and Classification of Diabetes Mellitus, WHO, Geneva, Switzerland, 1999.
  16. G. G. Gensini, “A more meaningful scoring system for determining the severity of coronary heart disease,” The American Journal of Cardiology, vol. 51, no. 3, p. 606, 1983. View at Publisher · View at Google Scholar · View at Scopus
  17. S. W. M. Shiu, S.-M. Xiao, Y. Wong, W.-S. Chow, K. S. L. Lam, and K. C. B. Tan, “Carbamylation of LDL and its relationship with myeloperoxidase in type 2 diabetes mellitus,” Clinical Science, vol. 126, no. 2, pp. 175–181, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. Ö. Düzgünçinar, B. Yavuz, T. Hazirolan et al., “Plasma myeloperoxidase is related to the severity of coronary artery disease,” Acta Cardiologica, vol. 63, no. 2, pp. 147–152, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. R. W. Alexander, “Leukocyte and endothelial angiotensin II type 1 receptors and microvascular thrombotic and inflammatory responses to hypercholesterolemia,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 2, pp. 240–241, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. R. El Bekay, M. Álvarez, J. Monteseirín et al., “Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-κB,” Blood, vol. 102, no. 2, pp. 662–671, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. L. P. Van der Zwan, P. G. Scheffer, J. M. Dekker, C. D. A. Stehouwer, R. J. Heine, and T. Teerlink, “Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure,” Hypertension, vol. 55, no. 6, pp. 1366–1372, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. X.-L. Liao, B. Lou, J. Ma, and M.-P. Wu, “Neutrophils activation can be diminished by apolipoprotein A-I,” Life Sciences, vol. 77, no. 3, pp. 325–335, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Mazor, R. Shurtz-Swirski, R. Farah et al., “Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients,” Atherosclerosis, vol. 197, no. 2, pp. 937–943, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Zhang, M.-L. Brennan, X. Fu et al., “Association between myeloperoxidase levels and risk of coronary artery disease,” Journal of the American Medical Association, vol. 286, no. 17, pp. 2136–2142, 2001. View at Publisher · View at Google Scholar · View at Scopus